| Literature DB >> 31483681 |
Nikos Xylourgidis1, Kisuk Min2, Farida Ahangari1, Guoying Yu1, Jose D Herazo-Maya1, Theodoros Karampitsakos3, Vassilis Aidinis4, Leonhard Binzenhöfer1, Demosthenes Bouros3, Anton M Bennett5, Naftali Kaminski1, Argyrios Tzouvelekis1,4.
Abstract
Mitogen-activated protein kinase (MAPK) phosphatase 5 (MKP-5) is a member of the dual-specificity family of protein tyrosine phosphatases that negatively regulates p38 MAPK and the JNK. MKP-5-deficient mice exhibit improved muscle repair and reduced fibrosis in an animal model of muscular dystrophy. Here, we asked whether the effects of MKP-5 on muscle fibrosis extend to other tissues. Using a bleomycin-induced model of pulmonary fibrosis, we found that MKP-5-deficient mice were protected from the development of lung fibrosis, expressed reduced levels of hydroxyproline and fibrogenic genes, and displayed marked polarization towards an M1-macrophage phenotype. We showed that the profibrogenic effects of the transforming growth factor-β1 (TGF-β1) were inhibited in MKP-5-deficient lung fibroblasts. MKP-5-deficient fibroblasts exhibited enhanced p38 MAPK activity, impaired Smad3 phosphorylation, increased Smad7 levels, and decreased expression of fibrogenic genes. Myofibroblast differentiation was attenuated in MKP-5-deficient fibroblasts. Finally, we found that MKP-5 expression was increased in idiopathic pulmonary fibrosis (IPF)-derived lung fibroblasts but not in whole IPF lungs. These data suggest that MKP-5 plays an essential role in promoting lung fibrosis. Our results couple MKP-5 with the TGF-β1 signaling machinery and imply that MKP-5 inhibition may serve as a therapeutic target for human lung fibrosis.Entities:
Keywords: MKP-5; fibroblast; homeostasis; kinase; phosphatase; pulmonary fibrosis
Mesh:
Substances:
Year: 2019 PMID: 31483681 PMCID: PMC6879900 DOI: 10.1152/ajplung.00264.2018
Source DB: PubMed Journal: Am J Physiol Lung Cell Mol Physiol ISSN: 1040-0605 Impact factor: 5.464